JP2021521171A - 治療用抗体の安定な製剤 - Google Patents
治療用抗体の安定な製剤 Download PDFInfo
- Publication number
- JP2021521171A JP2021521171A JP2020555466A JP2020555466A JP2021521171A JP 2021521171 A JP2021521171 A JP 2021521171A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2020555466 A JP2020555466 A JP 2020555466A JP 2021521171 A JP2021521171 A JP 2021521171A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- preparation
- sugar
- vedolizumab
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 title description 32
- 238000009472 formulation Methods 0.000 title description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 51
- 235000000346 sugar Nutrition 0.000 claims abstract description 29
- 150000001413 amino acids Chemical class 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- 239000007853 buffer solution Substances 0.000 claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 9
- 239000000872 buffer Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 8
- 239000012634 fragment Substances 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 229960004914 vedolizumab Drugs 0.000 description 28
- 238000001542 size-exclusion chromatography Methods 0.000 description 15
- 239000000178 monomer Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 150000008163 sugars Chemical class 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000011179 visual inspection Methods 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012430 stability testing Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008181 tonicity modifier Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700029228 Immunoglobulin Heavy Chain Genes Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
Description
本発明は、抗体分子の安定な製剤であって、ここで上記抗体は、最小限の賦形剤で安定化される製剤に関する。開示される製剤は、凍結乾燥形態および液体形態と適合性であり、静脈内および/または皮下の投与経路にも適している。
過去20年間で、組換えDNA技術は、多くのタンパク質、特に、抗体治療薬の商業化をもたらしてきた。これらの治療用抗体の有効性は、安定性、投与経路ならびにそれらの投与形態および濃度に大きく依存する。これは、次に、治療用抗体が治療用抗体の安定性および活性を保持するように適切に製剤化されることを必要とする。
本発明は、緩衝液、糖および界面活性剤を含む抗体の安定な薬学的製剤であって、ここで上記製剤が、遊離アミノ酸および塩を欠く製剤を開示する。本発明に従う抗体は、α4β7に結合する。
定義
用語「抗体」とは、ジスルフィド結合によって相互に接続される少なくとも2つの重(H)鎖および2つの軽(L)鎖を含む糖タンパク質、またはその抗原結合部分をいう。「抗体」は、本明細書で使用される場合、抗体全体または任意の抗原結合フラグメント(すなわち、「抗原結合部分」)またはその融合タンパク質を包含する。
本発明は、緩衝液、糖および界面活性剤を含む抗体の安定な薬学的製剤であって、ここで上記製剤は、遊離アミノ酸および塩を欠く製剤を開示する。
ベドリズマブの安定性に対するアミノ酸を伴うおよび伴わない種々の糖の濃度の影響を理解するために、異なる糖(例えば、スクロース、トレハロースおよびソルビトール)を有する製剤を調製した。ヒスチジン緩衝液バックグランド中の濃縮ベドリズマブの一部を、20mM リン酸緩衝液へと緩衝液交換した。その後、糖およびポリソルベートを、ヒスチジン緩衝液バックグラウンドおよびリン酸緩衝液バックグラウンドに存在するベドリズマブ製剤に添加した。アルギニンを遊離アミノ酸として選択し、ベドリズマブの安定化における遊離アミノ酸の効果を理解するために、数種の糖含有ベドリズマブ製剤に添加した。
表1: 糖を含み、アミノ酸を伴うおよび伴わないベドリズマブ製剤の組成
スクロース 60mg/mlおよび界面活性剤を含むベドリズマブ製剤の安定性に対する塩の効果を理解するために、50mM 塩化ナトリウムを、上記ベドリズマブ製剤のうちの1つに添加した。上記製剤の詳細を、表3に示す。上記サンプル全てを、50℃で2週間の加速安定性試験に供した。その後、上記サンプルを、低分子量(LMW)種またはフラグメント、高分子量(HMW)種または凝集物、およびモノマー含有量[結果を図2(a)〜(c)に示す]についてサイズ排除クロマトグラフィー(SEC)を使用して分析した。上記ベドリズマブサンプルの目視検査データを、表4に示す。
表3: 実施例2に従って調製したベドリズマブ製剤の組成
スクロース 60mg/ml、50mM アルギニンおよび界面活性剤を含むベドリズマブ製剤に対する異なる緩衝液バックグラウンドの効果を理解するために、種々の緩衝液を調製し、ベドリズマブの同じ組成物を、異なる緩衝液バックグラウンドにおいて製剤化した。上記製剤の詳細を、表5に示す。上記サンプル全てを、50℃で2週間の加速安定性試験に供した。その後、上記サンプルを、低分子量(LMW/フラグメント)種、高分子量種(HMW/凝集物)、およびモノマー含有量[結果を図3(a)〜(c)に示す]についてサイズ排除クロマトグラフィー(SEC)を使用して分析した。上記ベドリズマブサンプルの目視検査データを、表6に示す。
表5: 異なる緩衝液バックグランドにおけるベドリズマブ製剤の組成
Claims (7)
- 緩衝液、糖および界面活性剤を含む抗体の安定な薬学的製剤であって、ここで前記製剤は、遊離アミノ酸および塩を欠く、製剤。
- 前記抗体は、治療用抗体であり、α4β7に結合する、請求項1に記載の抗体製剤。
- 緩衝液、糖および界面活性剤を含むα4β7抗体の安定な薬学的製剤であって、ここで前記製剤は、遊離アミノ酸および塩を欠く、製剤。
- 前記糖の濃度は、60mg/mlである、請求項3に記載のα4β7抗体製剤。
- 前記抗体の濃度は、約50mg/ml〜約200mg/mlである、請求項3に記載のα4β7抗体製剤。
- 前記糖は、スクロース、トレハロース、またはソルビトールである、請求項1または3に記載の抗体製剤。
- 液体製剤または凍結乾燥製剤である、請求項1または3に記載の抗体製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841013647 | 2018-04-10 | ||
IN201841013647 | 2018-04-10 | ||
PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021521171A true JP2021521171A (ja) | 2021-08-26 |
JPWO2019198101A5 JPWO2019198101A5 (ja) | 2022-04-15 |
Family
ID=68164106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020555466A Pending JP2021521171A (ja) | 2018-04-10 | 2019-04-10 | 治療用抗体の安定な製剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210401982A1 (ja) |
EP (1) | EP3773696A4 (ja) |
JP (1) | JP2021521171A (ja) |
CN (1) | CN112292146A (ja) |
AU (1) | AU2019251453A1 (ja) |
BR (1) | BR112020020703A2 (ja) |
CO (1) | CO2020013571A2 (ja) |
SG (1) | SG11202009876TA (ja) |
WO (1) | WO2019198101A1 (ja) |
ZA (1) | ZA202006264B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3773695A4 (en) * | 2018-04-10 | 2021-12-22 | Dr. Reddy's Laboratories Ltd. | STABLE ANTIBODY FORMULATION |
EP4346899A1 (en) * | 2021-06-04 | 2024-04-10 | Polpharma Biologics S.A. | Vedolizumab formulation |
WO2023126411A1 (en) * | 2021-12-27 | 2023-07-06 | Polpharma Biologics S.A. | Vedolizumab formulation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530003A (ja) * | 2007-06-14 | 2010-09-02 | エラン ファーマシューティカルズ,インコーポレイテッド | 凍結乾燥免疫グロブリン製剤および調製方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2234600B1 (en) * | 2007-12-21 | 2014-08-20 | F. Hoffmann-La Roche AG | Antibody formulation |
MX354101B (es) * | 2011-05-02 | 2018-02-13 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI -A4ß7. |
UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
-
2019
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt unknown
- 2019-04-10 US US17/045,406 patent/US20210401982A1/en active Pending
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en unknown
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530003A (ja) * | 2007-06-14 | 2010-09-02 | エラン ファーマシューティカルズ,インコーポレイテッド | 凍結乾燥免疫グロブリン製剤および調製方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112292146A (zh) | 2021-01-29 |
AU2019251453A2 (en) | 2020-12-03 |
SG11202009876TA (en) | 2020-11-27 |
EP3773696A1 (en) | 2021-02-17 |
BR112020020703A2 (pt) | 2021-01-12 |
ZA202006264B (en) | 2022-09-28 |
WO2019198101A1 (en) | 2019-10-17 |
US20210401982A1 (en) | 2021-12-30 |
CO2020013571A2 (es) | 2021-01-18 |
EP3773696A4 (en) | 2021-12-29 |
AU2019251453A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021521171A (ja) | 治療用抗体の安定な製剤 | |
US11639391B2 (en) | Stable liquid pharmaceutical composition | |
JP2024001364A (ja) | 抗体製剤 | |
JP2024023468A (ja) | 安定な融合タンパク質製剤 | |
WO2022101935A1 (en) | Stable aqueous high concentration formulation of integrin antibody | |
JP2022551622A (ja) | インテグリン抗体の安定な製剤 | |
AU2022271025A1 (en) | A method of improving stability of an antibody formulation | |
WO2022123603A1 (en) | Stable aqueous buffer free formulation of an integrin antibody | |
JP2021521168A (ja) | 安定な抗体製剤 | |
WO2023037384A1 (en) | Formulations of immune check point inhibitors or like | |
WO2023031970A1 (en) | A pharmaceutical formulation of immune check point inhibitors | |
WO2023037383A1 (en) | Formulations of immune check point inhibitors | |
WO2024023843A1 (en) | A pharmaceutical formulation of a therapeuticantibody and preparations thereof | |
WO2022113105A1 (en) | Stable therapeutic protein formulation and methods of making the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220407 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220407 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230125 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230814 |